sábado, 7 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Is This the Right Time to Rebalance Your Portfolio?

View original at nasdaq.com
Is This the Right Time to Rebalance Your Portfolio? Key Points Some investors think it’s prudent to prune their top stocks in a bull market…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI could create the world's first trillionaire

    60% confidence
  • Has been invested in stocks for nearly two decades and has never regularly rebalanced portfolio

    60% confidence
  • Everybody in the world is a long-term investor until the market goes down

    60% confidence
  • Stock Advisor analyst team identified 10 best stocks for investors to buy now, and Nvidia was not one of them

    60% confidence
  • Amazon accounts for over 10% of his portfolio

    60% confidence
  • Believes in letting the winners ride instead of selling them too early for the sake of diversification

    60% confidence
  • There is a little-known company called an 'Indispensable Monopoly' providing critical technology both Nvidia and Intel need

    60% confidence
  • Does not plan to prune top stocks anytime soon

    60% confidence

Data points we hold from this source

S&P 500 · total return199 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is This the Right Time to Rebalance Your Portfolio? — Source | Via News | es.VIA.NEWS